The Hempshire Group, Inc. (HMPSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Hempshire Group, Inc. (HMPSF) with AI Score 41/100 (Weak). The Hempshire Group, Inc. is involved in sourcing, manufacturing, branding, and processing pharmaceutical-grade hemp and CBD products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026The Hempshire Group, Inc. (HMPSF) Healthcare & Pipeline Overview
The Hempshire Group, Inc., established in 2019, focuses on the pharmaceutical-grade hemp and CBD product sector. Operating with a small team, the company engages in sourcing, manufacturing, and branding, distinguishing itself in the competitive specialty and generic drug manufacturing industry through its focus on hemp-derived products.
Investment Thesis
The Hempshire Group, Inc. presents a high-risk, high-reward investment profile. The company's negative P/E ratio of -1.97 and a profit margin of -7300.9% indicate significant challenges in achieving profitability. However, its gross margin of 28.8% suggests potential in its core operations if costs can be managed effectively. A beta of 0.12 indicates low volatility compared to the market. Growth catalysts include potential expansion of its product line and increased market penetration in the growing CBD sector. The company's small size and limited resources pose risks, but successful execution of its business plan could lead to substantial returns. Investors should carefully consider the company's financial position and competitive landscape before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion, indicating a micro-cap company.
- Negative P/E ratio of -1.97, reflecting current losses.
- Profit margin of -7300.9%, highlighting significant operational inefficiencies.
- Gross margin of 28.8%, suggesting potential for profitability with improved cost management.
- Beta of 0.12, indicating lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Focus on pharmaceutical-grade hemp and CBD products.
- Established brand in a growing market.
- Proprietary processing techniques.
- Experienced management team.
Weaknesses
- Small size and limited resources.
- Negative profitability and high losses.
- Reliance on a niche market.
- Limited distribution network.
Catalysts
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities for Hempshire.
- Ongoing: Expansion of product line to include new CBD-infused products.
- Ongoing: Strategic partnerships with established pharmaceutical companies or retailers.
Risks
- Potential: Intense competition in the CBD market could erode market share.
- Potential: Regulatory uncertainty and changing laws could negatively impact operations.
- Ongoing: Fluctuations in hemp prices could affect profitability.
- Ongoing: Limited financial resources may hinder growth initiatives.
- Potential: Negative P/E ratio and profit margin indicate financial instability.
Growth Opportunities
- Expansion of Product Line: Hempshire can expand its product line to include a wider range of CBD-infused products, such as topicals, edibles, and beverages. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. By diversifying its offerings, Hempshire can attract a broader customer base and increase revenue streams. Successful product development and marketing will be crucial for capturing market share.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies or retailers could provide Hempshire with access to wider distribution networks and increased brand visibility. Collaborations can also facilitate research and development efforts, leading to innovative product formulations. The timeline for establishing such partnerships is dependent on negotiation and due diligence processes, but could yield significant benefits within the next 1-2 years.
- International Expansion: Exploring opportunities to expand into international markets, particularly in Europe and Asia, where the demand for CBD products is growing, represents a significant growth driver. Navigating regulatory requirements and establishing distribution channels in new markets will be essential for successful international expansion. This initiative could take 2-3 years to fully implement, but offers long-term growth potential.
- Focus on Research and Development: Investing in research and development to create novel CBD formulations and delivery methods can provide Hempshire with a competitive advantage. Developing proprietary technologies and intellectual property can also attract investment and partnership opportunities. The timeline for R&D initiatives can vary depending on the complexity of the projects, but could yield significant results within 3-5 years.
- Direct-to-Consumer Sales: Establishing a strong online presence and direct-to-consumer sales channel can improve margins and provide greater control over the customer experience. Investing in e-commerce infrastructure and digital marketing can drive online sales and build brand loyalty. This initiative can be implemented relatively quickly, with noticeable results within the next 6-12 months.
Opportunities
- Expansion of product line.
- Strategic partnerships with larger companies.
- International market expansion.
- Increased research and development.
Threats
- Intense competition in the CBD market.
- Regulatory uncertainty and changing laws.
- Fluctuations in hemp prices.
- Economic downturn affecting consumer spending.
Competitive Advantages
- Focus on pharmaceutical-grade quality.
- Specialization in hemp and CBD products.
- Established branding and marketing strategies.
- Proprietary processing techniques.
About HMPSF
The Hempshire Group, Inc., founded in 2019 and based in Palm Springs, California, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. The company is involved in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Hempshire's focus is on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. The company's operations encompass the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. With a small team of 8 employees, Hempshire navigates the complexities of the pharmaceutical industry, targeting consumers seeking hemp and CBD-based health and wellness solutions. The company's strategic focus on pharmaceutical-grade products underscores a commitment to quality and regulatory compliance, differentiating it from other players in the hemp and CBD market.
What They Do
- Sources pharmaceutical-grade hemp.
- Manufactures CBD products.
- Brands and markets its products.
- Processes hemp for various applications.
- Focuses on the healthcare sector.
- Operates in the specialty and generic drug manufacturing industry.
Business Model
- Sourcing high-quality hemp.
- Manufacturing CBD products.
- Branding and marketing for direct sales and distribution.
- Processing hemp for pharmaceutical applications.
Industry Context
The Hempshire Group, Inc. operates in the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for alternative medicines and wellness products. The CBD market, in particular, is expanding rapidly, but faces regulatory uncertainty and intense competition. Hempshire's focus on pharmaceutical-grade hemp and CBD products positions it within a niche segment that emphasizes quality and compliance. The company competes with both established pharmaceutical companies and smaller, specialized CBD manufacturers. Success in this market requires effective branding, distribution, and adherence to evolving regulatory standards.
Key Customers
- Consumers seeking hemp-based wellness products.
- Patients looking for alternative treatments.
- Retailers and distributors of health and wellness products.
Financials
Chart & Info
The Hempshire Group, Inc. (HMPSF) stock price: Price data unavailable
Latest News
No recent news available for HMPSF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HMPSF.
Price Targets
Wall Street price target analysis for HMPSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HMPSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shawn Balaghi
CEO
Shawn Balaghi is the CEO of The Hempshire Group, Inc. His background includes experience in managing and developing businesses, with a focus on the healthcare and wellness sectors. He has been instrumental in guiding the company's strategic direction and overseeing its operations. Balaghi's leadership is focused on driving innovation and growth within the competitive CBD market.
Track Record: Under Shawn Balaghi's leadership, The Hempshire Group, Inc. has focused on establishing a presence in the pharmaceutical-grade hemp and CBD market. Key milestones include developing a range of CBD products and establishing partnerships with distributors. Balaghi's strategic decisions have aimed at positioning the company for long-term growth and success in the evolving CBD industry.
HMPSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that The Hempshire Group, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk and lower liquidity compared to listed exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure requirements.
- Lower liquidity and potential price volatility.
- Higher risk of fraud or mismanagement.
- Potential for delisting or trading suspension.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulatory requirements.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established business operations since 2019.
- Focus on pharmaceutical-grade products.
- Presence in the growing CBD market.
- Active engagement with investors and stakeholders.
HMPSF Healthcare Stock FAQ
What does The Hempshire Group, Inc. do?
The Hempshire Group, Inc. engages in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Operating in the healthcare sector, the company focuses on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. Hempshire's business model encompasses the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. The company targets consumers seeking hemp and CBD-based health and wellness solutions.
What do analysts say about HMPSF stock?
As of 2026-03-17, there is no readily available analyst consensus on HMPSF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, indicate financial challenges. Growth considerations include the potential for expansion in the CBD market and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with investing in micro-cap OTC stocks before making any investment decisions.
What are the main risks for HMPSF?
The main risks for The Hempshire Group, Inc. include intense competition in the CBD market, regulatory uncertainty and changing laws, fluctuations in hemp prices, and limited financial resources. The company's negative P/E ratio and profit margin also indicate financial instability. As an OTC-listed company, HMPSF faces additional risks related to liquidity, disclosure requirements, and regulatory oversight. Investors should carefully consider these risks before investing in HMPSF stock.
What are the key factors to evaluate for HMPSF?
The Hempshire Group, Inc. (HMPSF) currently holds an AI score of 41/100, indicating low score. Key strength: Focus on pharmaceutical-grade hemp and CBD products.. Primary risk to monitor: Potential: Intense competition in the CBD market could erode market share.. This is not financial advice.
How frequently does HMPSF data refresh on this page?
HMPSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HMPSF's recent stock price performance?
Recent price movement in The Hempshire Group, Inc. (HMPSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on pharmaceutical-grade hemp and CBD products.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HMPSF overvalued or undervalued right now?
Determining whether The Hempshire Group, Inc. (HMPSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HMPSF?
Before investing in The Hempshire Group, Inc. (HMPSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.